FTC/DoJ jurisdiction
This article was originally published in The Gray Sheet
Executive Summary
Devices, pharmaceuticals and biotechnology will be subject to Federal Trade Commission antitrust clearance processes under an agreement announced by the agencies March 5. The new process allocates responsibilities based on industry, rather than on the agencies' historical experience in commercial sectors...